The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for NuMED sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
NuMED operates as a medical equipment company that develops, manufactures and markets cardiovascular medical products. The company offers various products which include angioplasty catheters, valvuloplasty catheters, PTA catheters, PTV catheters, pulmonary catheters, aortic valvuloplasty catheters, pediatric valvuloplasty catheters, atrioseptostomy catheters, sizing catheters, angiographic catheters, mitral valvuloplasty catheters, dacryocystoplasty catheters, and stent placement products. Its other products comprise prototype products, catheter materials, latex balloon catheters, high-pressure balloon catheters, conductance catheters, PTCA catheters, OB and GYN catheters, PTV catheters, and other custom designed catheters. NuMED offers various services such as catheter research and development, design facility testing, FDA testing, catheter designing and catheter configuration services. The company operates in the US and Canada. NuMED is headquartered in Hopkinton, New York, the US. Key subsidiaries of NuMED include NuMED Canada.
The key metrics of NuMED related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As NuMED is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as NuMED.
For a detailed understanding of the performance of NuMED, buy the report here.